Chad Oh - 17 Feb 2026 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: AEON
Reported as of: 17 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2026, 20:13:33 UTC
Prior SEC filing: 23 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Alexander Wilson, as Attorney-in-Fact, for Chad Oh

Key filing fact

Chad Oh filed Form 4 for AEON Biopharma, Inc. (AEON) on 11 Mar 2026.

Key facts

This page summarizes Chad Oh's Form 4 filing for AEON Biopharma, Inc. (AEON).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 11 Mar 2026, 20:13.

Change

Previous filing in this sequence was filed on 23 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001882166 Primary reporting owner

Oh Chad

Relationship: CHIEF MEDICAL OFFICER
Address: C/O AEON BIOPHARMA, INC., 5 PARK PLAZA, SUITE 1750, IRVINE
Signature: /s/ Alexander Wilson, as Attorney-in-Fact, for Chad Oh
Signature date: 11 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AEON transaction

Class A Common Stock

Award

Transaction value
Shares: +862,500
Change %: +21223%
Price: $0.000000^*
Shares after: 866,564
Date: 17 Feb 2026
Ownership: Direct
Footnotes: F1

AEON transaction

Class A Common Stock

Award

Transaction value
Shares: +1,316,872
Change %: +152%
Price: $0.000000^*
Shares after: 2,183,436
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

Footnote F2

Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.